Alnylam Pharmaceuticals (ALNY) Research & Development (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Research & Development came in at $413.1 million in Q2 2026, up 27.66% YoY from $323.6 million in Q2 2025, and up 13.23% on a QoQ basis from $364.9 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Research & Development (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Research & Development data on file, last reported at $413.1 million in Q2 2026.
- Quarterly Research & Development rose 27.66% year-over-year to $413.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 30.11% YoY) and the FY2025 annual result came in at $1.3 billion, up 17.19% from the prior year.
- Research & Development grew to $413.1 million in Q2 2026, from $364.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $413.1 million in Q2 2026 to a low of $169.9 million in Q1 2022.
- A 5-year average of $284.0 million and a median of $268.0 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development retreated 8.61% — and 2026, when it surged 37.62%.
- Tracing ALNY's Research & Development over 5 years: stood at $262.0 million in 2022, then gained by 3.86% to $272.1 million in 2023, then climbed by 10.3% to $300.2 million in 2024, then climbed by 24.0% to $372.2 million in 2025, then gained by 10.99% to $413.1 million in 2026.
- The last three Research & Development figures came in at $413.1 million (Q2 2026), $364.9 million (Q1 2026), and $372.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 202.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 413.13 Mn |
| Mar 31, 2026 | 364.87 Mn |
| Dec 31, 2025 | 372.22 Mn |
| Sep 30, 2025 | 358.81 Mn |
| Jun 30, 2025 | 323.62 Mn |
| Mar 31, 2025 | 265.12 Mn |
| Dec 31, 2024 | 300.17 Mn |
| Sep 30, 2024 | 270.93 Mn |
| Jun 30, 2024 | 294.14 Mn |
| Mar 31, 2024 | 261.00 Mn |
| Dec 31, 2023 | 272.14 Mn |
| Sep 30, 2023 | 253.18 Mn |
| Jun 30, 2023 | 248.53 Mn |
| Mar 31, 2023 | 230.57 Mn |
| Dec 31, 2022 | 262.04 Mn |
| Sep 30, 2022 | 245.37 Mn |
| Jun 30, 2022 | 205.71 Mn |
| Mar 31, 2022 | 169.89 Mn |
| Dec 31, 2021 | 229.05 Mn |
| Sep 30, 2021 | 194.57 Mn |